March 20, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more

March 14, 2018 Uncategorized

Save the date: Roche Analyst Event at ASCO 2018

Basel, 14 March 2018 Save the date: Roche Analyst Event at ASCO 2018 Monday, 4 June 2018 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (1 – 5 June... Read more

March 8, 2018 Uncategorized

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 08 March 2018 Changes to the Roche Enlarged Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that John C. Reed (1958), MD, PhD, Head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the United States effective 2... Read more

March 8, 2018 PR/Corporate

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 08 March 2018 Changes to the Roche Enlarged Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that John C. Reed (1958), MD, PhD, Head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the United States effective 2... Read more

February 27, 2018 Uncategorized

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors

Basel, 27 February 2018 European Commission approves Roche’s Hemlibra for people with haemophilia A with inhibitors First new medicine in over 20 years to treat people with haemophilia A with inhibitors in Europe Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies in adults, adolescents and children Once-weekly... Read more

February 27, 2018 Uncategorized

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors

Basel, 27 February 2018 European Commission approves Roche’s Hemlibra for people with haemophilia A with inhibitors First new medicine in over 20 years to treat people with haemophilia A with inhibitors in Europe Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies in adults, adolescents and children Once-weekly... Read more

February 15, 2018 M&A, Partnerships

Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer

Basel, 15 February 2018 Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer Acquisition will bring together two companies committed to improving the lives of cancer patients through the evolving field of healthcare data and analytics The companies will leverage their combined expertise to advance the... Read more

February 14, 2018 Acad, Gov/Utilities

FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris

Basel, 14 February 2018 FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris Pemphigus vulgaris (PV) is a life-threatening, autoimmune condition with limited treatment options1 The FDA previously granted Breakthrough Therapy Designation and Orphan Drug Designation for MabThera/Rituxan in PV Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food... Read more

February 12, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema

Basel, 12 February 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema RG7716 is the first bispecific antibody designed specifically for the treatment of retinal eye diseases RG7716 demonstrated clinically meaningful and statistically significant improvements in visual acuity Key secondary and exploratory anatomical outcomes were... Read more

February 8, 2018 M&A, Partnerships

Roche purchases shares in tender offer for Ignyta, Inc.

Basel, 08 February 2018 Roche purchases shares in tender offer for Ignyta, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common... Read more